Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia.

International Journal of Hematologic Oncology Pub Date : 2020-09-04 DOI:10.2217/ijh-2020-0009

Brynne Underwood, Qiuhong Zhao, Alison R Walker, Alice S Mims, Sumithira Vasu, Meixiao Long, Tamanna Z Haque, Bradley W Blaser, Nicole R Grieselhuber, Sarah A Wall, Gregory K Behbehani, James S Blachly, Karilyn Larkin, John C Byrd, Ramiro Garzon, Tzu-Fei Wang, Bhavana Bhatnagar

{"title":"Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia.","authors":"Brynne Underwood, Qiuhong Zhao, Alison R Walker, Alice S Mims, Sumithira Vasu, Meixiao Long, Tamanna Z Haque, Bradley W Blaser, Nicole R Grieselhuber, Sarah A Wall, Gregory K Behbehani, James S Blachly, Karilyn Larkin, John C Byrd, Ramiro Garzon, Tzu-Fei Wang, Bhavana Bhatnagar","doi":"10.2217/ijh-2020-0009","DOIUrl":null,"url":null,"abstract":"Aim: There are limited data describing incidence of symptomatic venous thromboembolism (VTE) in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) patients receiving peg-asparaginase.Materials & methods: Single-institution retrospective analysis of 44 AYA ALL patients treated with peg-asparaginase. Rates of VTE and proposed risk factors were assessed.Results: 18 patients (41%) had a symptomatic VTE following peg-asparaginase. The cumulative incidence rate was 25% (95% CI: 13-38%) within 30 days of the initial dose. Personal history of thrombosis was statistically significantly associated with an increased risk of VTE with HR of 2.73 (95% CI: 1.40-5.33, p = 0.003) after adjusting for gender.Conclusion: These data indicate a high rate of VTE in the AYA ALL population following treatment with peg-asparaginase.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"9 3","pages":"IJH28"},"PeriodicalIF":0.0000,"publicationDate":"2020-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521187/pdf/","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hematologic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/ijh-2020-0009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 8

Abstract

Aim: There are limited data describing incidence of symptomatic venous thromboembolism (VTE) in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) patients receiving peg-asparaginase.

Materials & methods: Single-institution retrospective analysis of 44 AYA ALL patients treated with peg-asparaginase. Rates of VTE and proposed risk factors were assessed.

Results: 18 patients (41%) had a symptomatic VTE following peg-asparaginase. The cumulative incidence rate was 25% (95% CI: 13-38%) within 30 days of the initial dose. Personal history of thrombosis was statistically significantly associated with an increased risk of VTE with HR of 2.73 (95% CI: 1.40-5.33, p = 0.003) after adjusting for gender.

Conclusion: These data indicate a high rate of VTE in the AYA ALL population following treatment with peg-asparaginase.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

急性淋巴细胞白血病青少年和青年患者使用peg-天冬酰胺酶后静脉血栓的发生率。

目的:关于青少年和年轻成人(AYA)急性淋巴细胞白血病(ALL)患者接受peg-天冬酰胺酶治疗的症状性静脉血栓栓塞(VTE)发生率的数据有限。材料与方法:对44例接受peg-天冬酰胺酶治疗的AYA ALL患者进行单机构回顾性分析。评估静脉血栓栓塞率和建议的危险因素。结果:18例(41%)患者在使用peg-天冬酰胺酶后出现症状性静脉血栓栓塞。初始剂量后30天内的累积发病率为25% (95% CI: 13-38%)。经性别调整后，个人血栓病史与静脉血栓栓塞风险增加有统计学意义，风险比为2.73 (95% CI: 1.40-5.33, p = 0.003)。结论:这些数据表明，在使用peg-天冬酰胺酶治疗后，AYA ALL人群的静脉血栓栓塞率很高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International Journal of Hematologic Oncology

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： International Journal of Hematologic Oncology welcomes unsolicited article proposals. Email us today to discuss the suitability of your research and our options for authors, including Accelerated Publication. Find out more about publishing open access with us here.